Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,567 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 38,198 · Balance 162,567 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 202,759 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 202,759 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 156,589 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 46,170 · Balance 156,589 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 194,786 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2021 Filed Nov 18, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $50.63 | $311,880.80 |
DisclosureSEC source: 0001437749-21-027005 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.95 to $51.16, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-027005 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-027005 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,160 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $47.96 | $295,433.60 |
DisclosureSEC source: 0001437749-21-027005 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.90 to $48.85, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-027005 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-023855 · rdgdoc.xml · derivative · entry 7 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,320 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $40.76 | $251,081.60 |
DisclosureSEC source: 0001437749-21-023855 · rdgdoc.xml · nonDerivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,664 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.70 to $41.54, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-023855 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-023855 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,480 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $39.91 | $245,845.60 |
DisclosureSEC source: 0001437749-21-023855 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,664 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.48 to $40.17, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-023855 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 895 | $39.92 | $35,728.40 |
DisclosureSEC source: 0001437749-21-023855 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,664 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 28, 2021 Filed Oct 1, 2021 00:16 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 505 | $43.12 | $21,775.60 |
DisclosureSEC source: 0001437749-21-022966 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,559 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 16, 2021 Filed Sep 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-022360 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,640 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| September 16, 2021 Filed Sep 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $46.10 | $283,976.00 |
DisclosureSEC source: 0001437749-21-022360 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.77 to $46.5 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2021 Filed Sep 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-022360 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2021 Filed Sep 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-022360 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,800 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| September 15, 2021 Filed Sep 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $49.01 | $301,901.60 |
DisclosureSEC source: 0001437749-21-022360 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.20 to $49.81 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 15, 2021 Filed Sep 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-022360 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-020458 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,960 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $44.80 | $275,968.00 |
DisclosureSEC source: 0001437749-21-020458 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.68 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-020458 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2021 Filed Aug 19, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-020458 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,120 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| August 16, 2021 Filed Aug 19, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $46.03 | $283,544.80 |
DisclosureSEC source: 0001437749-21-020458 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.83 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 19, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-020458 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-017168 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,280 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $44.04 | $271,286.40 |
DisclosureSEC source: 0001437749-21-017168 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.62 to $44.78 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-017168 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,165 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-017168 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,440 Underlying: Common Stock · 6,165 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,165 | $42.74 | $263,492.10 |
DisclosureSEC source: 0001437749-21-017168 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.15 to $43.78 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,165 | $1.64 | $10,110.60 |
DisclosureSEC source: 0001437749-21-017168 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 502 | $43.75 | $21,962.50 |
DisclosureSEC source: 0001437749-21-016265 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionShare Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-014985 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,605 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $39.26 | $241,841.60 |
DisclosureSEC source: 0001437749-21-014985 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.92 to $39.70 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-014985 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionShare Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-014985 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,765 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $39.38 | $242,580.80 |
DisclosureSEC source: 0001437749-21-014985 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.55 to $39.80 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-014985 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-012571 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,925 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $29.68 | $182,828.80 |
DisclosureSEC source: 0001437749-21-012571 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.90 to $30.12 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-012571 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-012571 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,085 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| May 13, 2021 Filed May 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $29.52 | $181,843.20 |
DisclosureSEC source: 0001437749-21-012571 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.02 to $30.70 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 13, 2021 Filed May 18, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-012571 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 00:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-009292 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,245 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 00:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $33.38 | $205,620.80 |
DisclosureSEC source: 0001437749-21-009292 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.92 to $33.78 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 00:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-009292 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 00:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-009292 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,405 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 00:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $33.76 | $207,961.60 |
DisclosureSEC source: 0001437749-21-009292 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.45 to $34.21 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 00:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-009292 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.